Leila Alland - Jul 7, 2021 Form 4 Insider Report for PMV Pharmaceuticals, Inc. (PMVP)

Role: Chief Medical Officer
Signature: /s/ Winston Kung, by power of attorney
Stock symbol: PMVP
Transactions as of: Jul 7, 2021
Transactions value $: -$113,613
Form type: 4
Date filed: 7/8/2021, 04:10 PM
Previous filing: May 27, 2021
Next filing: Aug 10, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PMVP	Common Stock	Options Exercise	$15.6K	+4K		$3.90	4K	Jul 7, 2021	Direct
transaction	PMVP	Common Stock	Sale	-$62.3K	-1.95K	-48.78%	$31.93	2.05K	Jul 7, 2021	Direct	F1, F2
transaction	PMVP	Common Stock	Sale	-$66.9K	-2.05K	-100%	$32.66	0	Jul 7, 2021	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PMVP	Employee Stock Option (right to buy)	Options Exercise	$0	-4K	-1.09%	$0.00	362K	Jul 7, 2021	Common Stock	4K	$3.90	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.455 to $32.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.455 to $32.835, inclusive.
F4	One-fourth of the shares subject to the option vested on December 3, 2020, and one forty-eighth of the shares subject to the option shall vest each month thereafter.